Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations.

نویسندگان

  • T Berghmans
  • F Pasleau
  • M Paesmans
  • Y Bonduelle
  • J Cadranel
  • I Cs Toth
  • C Garcia
  • V Giner
  • S Holbrechts
  • J J Lafitte
  • J Lecomte
  • I Louviaux
  • E Markiewicz
  • A P Meert
  • M Richez
  • M Roelandts
  • A Scherpereel
  • Ch Tulippe
  • P Van Houtte
  • P Van Schil
  • C Wachters
  • V Westeel
  • J P Sculier
چکیده

The present systematic review was performed under the auspices of the European Lung Cancer Working Party (ELCWP) in order to determine the role of early intermediate criteria (surrogate markers), instead of survival, in determining treatment efficacy in patients with lung cancer. Initially, the level of evidence for the use of overall survival to evaluate treatment efficacy was reviewed. Nine questions were then formulated by the ELCWP. After reviewing the literature with experts on these questions, it can be concluded that overall survival is still the best criterion for predicting treatment efficacy in lung cancer. Some intermediate criteria can be early predictors, if not surrogates, for survival, despite limitations in their potential application: these include time to progression, progression-free survival, objective response, local control after radiotherapy, downstaging in locally advanced nonsmall cell lung cancer (NSCLC), complete resection and pathological TNM in resected NSCLC, and a few circulating markers. Other criteria assessed in these recommendations are not currently adequate surrogates of survival in lung cancer.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Predicting Survival of Patients with Lung Cancer Using Improved Adaptive Neuro-Fuzzy Inference System

Introduction: Lung cancer is the main cause of mortality in both genders worldwide. This disease is caused by the uncontrollable growth and development of cells in both or one of the lungs. Although the early diagnosis of this cancer is not an easy task, the earlier it is diagnosed, the higher will be the chance of treating. The objective of this study was to develop an optimized prediction mod...

متن کامل

Predicting Survival of Patients with Lung Cancer Using Improved Adaptive Neuro-Fuzzy Inference System

Introduction: Lung cancer is the main cause of mortality in both genders worldwide. This disease is caused by the uncontrollable growth and development of cells in both or one of the lungs. Although the early diagnosis of this cancer is not an easy task, the earlier it is diagnosed, the higher will be the chance of treating. The objective of this study was to develop an optimized prediction mod...

متن کامل

Prognostic value of various metabolic parameters on pre-treatment 18-F-FDG PET/CT in patients with stage I-III non-small cell lung cancer

Background: the aim of this study was to investigate the prognostic value of 18Fluorine-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) parameters in both overall survival and progression-free survival in Stage I-III non-small cell lung cancer (NSCLC). Materials and Methods: In this retrospective study, 267 patients who were diagnosed as Stage I-III non-smal...

متن کامل

Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics

Here, we used an informatics-based approach to identify novel biomarkers of overall survival and tumor progression in non-small cell lung cancer (NSCLC) patients. We determined whether nuclear-encoded genes associated with mitochondrial biogenesis and function can be used to effectively predict clinical outcome in lung cancer. This strategy allowed us to directly provide in silico validation of...

متن کامل

Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?

Platinum-based doublet chemotherapy prolongs survival and improves quality of life as first-line treatment for non-selected and good performance status patients with advanced nonsmall cell lung cancer (NSCLC) [1]. However, the survival benefit is limited, even if this combination is the standard of care for decades, no clinically relevant predictive biomarkers have been discovered so far. The i...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The European respiratory journal

دوره 39 1  شماره 

صفحات  -

تاریخ انتشار 2012